We are an information and analytics company focused on pharmaceutical reimbursement.

We are an information and analytics company focused on pharmaceutical reimbursement.

News & Updates

Real Endpoints Recent Developments

Move over Gilead? AbbVie could bring serious competition to HCV market.

Posted by Julie Eagle on Oct 13, 2014

Gilead’s Harvoni might be the top overall performer, says RxScorecard™, but a discounted Triple regimen from AbbVie could mount major challenge. Gilead’s Harvoni (sofosbuvir/ledipasvir combination) is the top overall scorer, according to RxScorecard, a drug-value...

Learn More

Roger Longman, Guest Commentary, BioCentury, Week of October 6, 2014

Posted by Julie Eagle on Oct 10, 2014

Price Cuts in HCV by Roger Longman, CEO, Real Endpoints. If you’ve heard or read anything about HCV, you’ll know the costs of covering the large population are very high – and will get worse. That’s certainly the subtext in announcements from...

Learn More

Roger Longman, Guest Commentary, BioCentury, Week of August 4, 2014

Posted by Julie Eagle on Aug 11, 2014

Biopharma’s Echo Chamber by Roger Longman, CEO, Real Endpoints. Either pharma helps its customers create the standards on which the full value of their drugs will be measured relative to their competitors – or they’ll have it done for them. Please...

Learn More

Roger Longman, Guest Commentary, BioCentury, Week of June 9, 2014

Posted by Julie Eagle on Jun 10, 2014

Cost Steamroller by Roger Longman, CEO, Real Endpoints. The challenge for biopharma companies is to make sure that cost is only one component of the assessment. Please click here to learn more and access the...

Learn More

Q&A: What the Deal Frenzy Says About Pharma’s Future – Wall Street Journal

Posted by Julie Eagle on Apr 28, 2014

Roger Longman was interviewed by the Wall Street Journal about the sudden flurry of M&A activity in the pharmaceutical industry over the last week. Read the full story here:...

Learn More

Evidence and Endpoints in Cancer: Can Both Payers and Regulators be Satisfied?

Posted by Melanie Senior on Mar 27, 2013

How can oncology drug developers design their trials to satisfy both regulators and payers, and thereby maximize both access and commercial success?  It’s an increasingly urgent question as cancer programs continue to dominate pipelines, and drugs bills. Yet “there’s...

Learn More